Tags: Partnership
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
October 17, 2019
Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
announcements
February 19, 2019
The ADDF and Harrington Discovery Institute Announce 2019 ADDF-Harrington Scholar Award
Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation announce a joint request for proposals for the 2019 ADDF-Harrington Scholar Award.
announcements
July 17, 2018
New Coalition of Philanthropists Including Bill Gates, Leonard Lauder Commit More Than $30 Million
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
announcements
May 10, 2018
$2.5 Million in New Funding Exemplifies ADDF’s Strategy
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
announcements
May 1, 2018
Partnership with FNIH Will Drive New Biomarkers for Alzheimer’s
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
announcements
March 28, 2018
ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award
Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.
announcements
March 13, 2018
Funding Supports New Approaches to Treat Multiple Types of Dementia
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
blog
January 2, 2018
Top Five Alzheimer’s Advances in 2017
Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.
announcements
October 3, 2017
New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation
The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.
announcements
June 7, 2017
ADDF and Science Exchange Launch ADDF ACCESS to Advance Research
New “CRO Finder” Connects Scientists with Specialized Resources
announcements
January 18, 2017
Expanded Partnership Increases Support for Drug Discovery
ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
announcements
May 13, 2016
Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.
announcements
February 2, 2016
ADDF Joins BIRAX Regenerative Medicine Initiative
The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s.
announcements
January 12, 2016
PsychoGenics and the ADDF Announce a Risk-Sharing Partnership for Preclinical Studies
We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs.
announcements
August 26, 2015
ADDF and Harrington Discovery Institute Announce 2015 Award Recipients
Collaboration advances development of therapeutics for the treatment of Alzheimer’s Disease.
announcements
August 12, 2015
Goodes Family & The ADDF Create New Prize for Alzheimer’s Drug Development Researchers
Melvin R. Goodes Prize supports innovative projects by top researchers while honoring the legacy of the former Warner-Lambert CEO.
announcements
August 6, 2015
Carmel Valley, California Winery Launches Two New Wines to Benefit the ADDF
Jarman Wines, a winery in Carmel Valley, will introduce two premium varietals to benefit the ADDF and to honor the matriarch of the family whose name graces the wines created for her.
blog
April 30, 2015
Partners for a Cure: Association for Frontotemporal Degeneration
Partnerships increase our funding power and our combined expertise—ultimately, ensuring that we can get to a cure for Alzheimer’s and related dementias faster.
announcements
February 11, 2015
ADDF Teams Up with Pfizer CTI to Support Discovery of Drugs for Alzheimer’s Disease
The ADDF and Pfizer’s Centers for Therapeutic Innovation are collaborating to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias.
announcements
December 11, 2014
Erectile Dysfunction Drug to Be Tested as Dementia Treatment
The ADDF and the Alzheimer's Society UK announced new funding to explore the possibility of using tadalafil, a commonly prescribed drug which treats erectile dysfunction, as the next treatment for dementia.
blog
December 4, 2014
The $3.3 Billion Case for Venture Philanthropy
The Cystic Fibrosis Foundation received a record-breaking $3.3 billion return on its early investment in research that led to the first FDA-approved drug to treat the causes of cystic fibrosis.
announcements
September 10, 2014
New Platform Powered by OnDeckBiotech Connects Researchers with Drug Discovery Expertise
The ADDF and OnDeckBiotech announced the relaunch of ADDF ACCESS as a new and improved platform to connect scientists with a virtual network of contract research organizations.
blog
June 27, 2014
Joining Forces to End Alzheimer’s
We joined the Accelerating Medicines Partnership to speed up drug development for Alzheimer's and other major diseases.
announcements
June 26, 2014
Leading Foundations Publish Recommendations to Accelerate Drug Repurposing
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.
announcements
June 26, 2014
Alzheimer’s Drug Discovery Foundation and OnDeckBiotech Partner to Expand ADDF ACCESS Network
The ADDF and OnDeckBiotech announced a strategic partnership to provide a new platform technology for ADDF ACCESS. Utilizing OnDeckBiotech's technology, ADDF ACCESS will increase the efficiency of contracting drug development services.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024